文献速递核素与放射性配体治疗肿瘤 PET/CT

单时间点剂量学在177Lu-DOTATATE/DOTATOC治疗儿童神经母细胞瘤中的可行性

Feasibility of Single Time Point Dosimetry Application in 177 Lu-DOTATATE/DOTATOC-treated Pediatric Neuroblastoma.
PubMed 文献 · Clin Nucl Med · 2025-06-17

本研究纳入24例接受1至2周期177Lu-DOTATATE或177Lu-DOTATOC治疗的儿童神经母细胞瘤患者,采用Hänscheid等提出的96小时单时间点(STPH)剂量学方法测量病灶和关键器官吸收剂量,并与标准多时间点(MTP)结果比较。结果显示,在177Lu-DOTATATE治疗患者中,STPH计算的吸收剂量与MTP的平均相对偏差绝对值在病灶、肾脏、骨髓、肝脏和脾脏均<10%,皮尔逊相关系数分别为0.99、0.93、0.97、0.84和0.84;在177Lu-DOTATOC治疗患者中,肾脏、脾脏和骨髓的平均相对偏差绝对值<10%,病灶、肾脏、骨髓、肝脏和脾脏的皮尔逊相关系数分别为0.97、0.77、0.35、0.48和0.93。结论认为96小时STPH方法可可靠替代MTP用于177Lu-DOTATATE治疗儿童NB患者的剂量学评估,并在177Lu-DOTATOC治疗的肾脏剂量学中表现良好。

要点

  • 24例儿童NB患者接受1至2周期177Lu-DOTATATE或177Lu-DOTATOC治疗,比较96小时STPH与MTP剂量学。
  • 177Lu-DOTATATE治疗患者中,STPH与MTP的平均相对偏差绝对值在病灶、肾脏、骨髓、肝脏和脾脏均<10%。
  • 177Lu-DOTATOC治疗患者中,肾脏、脾脏和骨髓的平均相对偏差绝对值<10%。

核心结论

  • 研究证实96小时STPH方法可可靠替代MTP用于177Lu-DOTATATE治疗儿童NB患者的剂量学评估,并在177Lu-DOTATOC治疗的肾脏剂量学中表现良好。

研究设计与样本

  • 共纳入24例接受1至2周期177Lu-DOTATATE或177Lu-DOTATOC治疗的儿童NB患者,采用96小时单时间点(STPH)剂量学方法测量病灶和关键器官吸收剂量,并与标准多时间点(MTP)结果比较。

主要发现

  • 在177Lu-DOTATATE治疗患者中,STPH计算的吸收剂量与MTP的平均相对偏差绝对值在病灶、肾脏、骨髓、肝脏和脾脏均<10%,皮尔逊相关系数分别为0.99、0.93、0.97、0.84和0.84。
  • 在177Lu-DOTATOC治疗患者中,肾脏、脾脏和骨髓的平均相对偏差绝对值<10%,病灶、肾脏、骨髓、肝脏和脾脏的皮尔逊相关系数分别为0.97、0.77、0.35、0.48和0.93。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 177 Lu-DOTATATE/DOTATOC peptide receptor radionuclide therapy (PRRT) has demonstrated potential for treating pediatric neuroblastoma (NB), and in clinical practice can be measured dosimetry by multi-time point (MTP) dosimetry. However, the high workload and limited patient compliance associated with MTP restrict its application. Consequently, single time point (STP) dosimetry approaches have emerged as a promising alternative, though their effectiveness in pediatric populations has not been thoroughly investigated. This study aimed to assess the dosimetric determination of 177 Lu-DOTATATE/DOTATOC in pediatric neuroblastoma patients to determine whether STP could serve as a viable replacement for MTP. PATIENTS AND METHODS: A total of 24 pediatric NB patients who received 1 to 2 cycles of 177 Lu-DOTATATE or 177 Lu-DOTATOC underwent dosimetric measurement of lesions and critical organs using the 96 hours single time point (STP H ) dosimetry method proposed by Hänscheid and colleagues. The results were compared with those obtained from standard MTP. RESULTS: In patients treated with 177 Lu-DOTATATE, the mean relative deviation absolute values of the STP H -calculated absorbed dose from MTP were <10% for lesions, kidneys, bone marrow, liver, and spleen, with Pearson correlation coefficients of 0.99, 0.93, 0.97, 0.84, and 0.84, respectively. In patients treated with 177 Lu-DOTATOC, the mean relative deviation absolute values for kidneys, spleen, and bone marrow were <10%, with Pearson correlation coefficients of 0.97, 0.77, 0.35, 0.48, and 0.93 for lesions, kidneys, bone marrow, liver, and spleen, respectively. CONCLUSIONS: The findings confirm that the 96 hours STP H method can reliably replace MTP for dosimetric assessment in pediatric NB patients treated with 177 Lu-DOTATATE and performed well in renal dosimetry for 177 Lu-DOTATOC therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sun X, Zheng F, Liu Y, et al. Feasibility of Single Time Point Dosimetry Application in 177 Lu-DOTATATE/DOTATOC-treated Pediatric Neuroblastoma. Clin Nucl Med. 2025. PMID: 40524361. doi:10.1097/RLU.0000000000006029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。